文献速递慢性肾脏病

连续测量成纤维细胞生长因子23与肾脏替代治疗需求风险:CRIC研究

Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study.
PubMed 文献 · Am J Kidney Dis · 2019-12-19

该病例队列研究纳入1,597名慢性肾功能不全队列研究参与者,最多5次年度羧基末端FGF-23测量,采用时间依赖逆概率加权离散时间失败模型分析。结果显示过去自然对数转换FGF-23均值每增加1个标准差,肾脏替代治疗风险HR为1.94(95%CI 1.51-2.49),FGF-23轨迹组与风险相关。

要点

  • 连续测量FGF-23升高与肾脏替代治疗需求风险独立相关。
  • 过去lnFGF-23均值每增加1个SD,KRT风险HR为1.94。
  • FGF-23快速上升轨迹组KRT风险约为稳定组的21倍。

核心结论

  • FGF-23水平升高与肾脏替代治疗需求风险独立相关。

研究设计与样本

  • 病例队列研究,纳入1,597名CRIC研究参与者,最多5次年度羧基末端FGF-23测量。

主要发现

  • 过去lnFGF-23均值每增加1个标准差,KRT风险HR为1.94(95%CI 1.51-2.49)。
  • 基线lnFGF-23每增加1个标准差,KRT风险HR为1.18(95%CI 1.02-1.37)。
  • 时间更新lnFGF-23每增加1个标准差,KRT风险HR为1.66(95%CI 1.49-1.86)。
  • 缓慢上升和快速上升FGF-23轨迹组KRT风险分别约为稳定组的3倍和21倍。

局限性

  • 存在残余混杂。
  • 缺乏完整FGF-23值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Studies using a single measurement of fibroblast growth factor 23 (FGF-23) suggest that elevated FGF-23 levels are associated with increased risk for requirement for kidney replacement therapy (KRT) in patients with chronic kidney disease. However, the data do not account for changes in FGF-23 levels as kidney disease progresses. STUDY DESIGN: Case-cohort study. SETTING & PARTICIPANTS: To evaluate the association between serial FGF-23 levels and risk for requiring KRT, our primary analysis included 1,597 individuals in the Chronic Renal Insufficiency Cohort Study who had up to 5 annual measurements of carboxy-terminal FGF-23. There were 1,135 randomly selected individuals, of whom 266 initiated KRT, and 462 individuals who initiated KRT outside the random subcohort. EXPOSURE: Serial FGF-23 measurements and FGF-23 trajectory group membership. OUTCOMES: Incident KRT. ANALYTICAL APPROACH: To handle time-dependent confounding, our primary analysis of time-updated FGF-23 levels used time-varying inverse probability weighting in a discrete time failure model. To compare our results with prior data, we used baseline and time-updated FGF-23 values in weighted Cox regression models. To examine the association of FGF-23 trajectory subgroups with risk for incident KRT, we used weighted Cox models with FGF-23 trajectory groups derived from group-based trajectory modeling as the exposure. RESULTS: In our primary analysis, the HR for the KRT outcome per 1 SD increase in the mean of natural log-transformed (ln)FGF-23 in the past was 1.94 (95% CI, 1.51-2.49). In weighted Cox models using baseline and time-updated values, elevated FGF-23 level was associated with increased risk for incident KRT (HRs per 1 SD ln[FGF-23] of 1.18 [95% CI, 1.02-1.37] for baseline and 1.66 [95% CI, 1.49-1.86] for time-updated). Membership in the slowly and rapidly increasing FGF-23 trajectory groups was associated with ∼3- and ∼21-fold higher risk for incident KRT compared to membership in the stable FGF-23 trajectory group. LIMITATIONS: Residual confounding and lack of intact FGF-23 values. CONCLUSIONS: Increasing FGF-23 levels are independently associated with increased risk for incident KRT.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Mehta R, Cai X, Lee J, et al. Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2019. PMID: 31864822. doi:10.1053/j.ajkd.2019.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。